[ivory-search id="184" title="Recordati AJAX Search Form"]

Mohamed Ladha

President and General Manager, North America
Read more

Ailyn Abin

Vice President North American Legal, Compliance and Government Affairs
Read more

Lori Larsen

Vice President, Finance and Administration
Read more

Mickey Baker

Vice President North American Business Operations
Read more

Jeroen Commissaris

Vice President, Oncology
Read more

Alessandro Albuquerque

CMO and Vice President Medical Affairs and Clinical Development
Read more

Max Johnson

General Manager, Canada
Read more

Becky Zenz

Vice President, Human Resources
Read more

Peter H. Strauss

Vice President Endocrinology Commercial Operations and Market Access
Read more

Nick DeLong

Vice President of North American Business Development & Portfolio Management
Read more

Carter Clanton

Vice President, Metabolic Diseases Commercial Operations
Read more

Weicheng Wu

Vice President, Regulatory Affairs and Quality Assurance (GCP/GPV)
Read more

Mohamed Ladha

President and General Manager, North America

Mohamed Ladha is the President and General Manager at Recordati Rare Diseases where is he is responsible for the US and Canadian business. During his career, Mr. Ladha has held numerous leadership positions globally in hematology/oncology and specialty care to oversee business in the US, Canada, EU, China, Emerging Markets, and Japan.


Mr. Ladha joined Recordati Rare Diseases from Oncopeptides, where he was the General Manager and Executive Vice President for the US Region Business Unit. Prior to Oncopeptides, he served in a series of leadership positions of increasing responsibility at companies including Vertex Pharmaceuticals, Pfizer, Schering-Plough, Merck & Company, Hospira, ARIAD Pharmaceuticals, Takeda Oncology, and Tocagen. Mr. Ladha started his career in basic science research focused in oncology at the Dana-Farber Cancer Institute.


Mr. Ladha graduated from Hampshire College with a Bachelor of Arts degree. He also holds professional/graduate degrees from Harvard University’s Kennedy School of Government and Northwestern University’s Kellogg School of Management.

Ailyn Abin

Vice President North American Legal, Compliance and Government Affairs

Ailyn Abin is Vice President, North American Legal and Compliance at Recordati Rare Diseases, where she is responsible for the development and delivery of the overall legal strategy, compliance program and overseeing advocacy and legislative strategy in support of the business. She has over 20 years of legal and industry experience. Most recently she served as Interim General Counsel for Pharmacosmos Therapeutics and spent over a decade at Celgene Corporation holding positions of increasing levels and responsibility. She also served as an Assistant U.S. Attorney for the District of New Jersey and began her career as a Litigation Associate at Drinker Biddle & Reath LLP.

 

Ms. Abin earned her B.A. degree from Rutgers University and her J.D. from Northeastern University School of Law.

Lori Larsen

Vice President, Finance and Administration

Lori Larsen, Vice President, Finance and Administration, joined Recordati Rare Diseases in 2014. Prior to joining the company, Lori had broad experience managing complex organizations with global operations. Prior roles included Group Financial Controller with Next Pharma in London, England as well as positions of increasing responsibility at Honeywell including as the Finance Director for Eastern Europe in Prague, Czech Republic.

 

Ms. Larsen received her Bachelor’s degree in Business Administration from Stephens College and her MBA from Arizona State University.

Mickey Baker

Vice President North American Business Operations

Mickey Baker is the Vice President of North American Business Operations where he leads Trade & Distribution, Pricing & Contracting, HEOR, and Government Affairs, in addition to other business operations activities. Prior to joining Recordati Rare Diseases, Mr. Baker was Head of US Market Access at EUSA Pharma.

 

Mr. Baker started his career in sales at Hoechst Marion Roussel, growing into roles of greater responsibility at Aventis, Sanofi, MGI Pharma, Entellus Medical, Trovita Health Science, Shire, Servier and EUSA Pharma. His industry experience includes Sales, Sales Training, Sales Management, Marketing and Market Access.

 

The majority of his 25-year career has been in the Oncology/Hematology specialty growing therapeutic and supportive care businesses in small to mid-sized organizations.

 

Mr. Baker graduated from the University of Minnesota with a Bachelor of Science degree in Business and completed the MBA program at the University of Florida.

Jeroen Commissaris

Vice President, Oncology

Jeroen Commissaris, of Dutch nationality, is the Vice President of Commercial Operations where he is responsible for leading Recordati Rare Diseases Oncology Franchise. During his career Mr. Commissaris has held numerous leadership positions focused on commercializing products across a variety of global regions, countries and therapeutic categories including Mental Health, Respiratory, Cardiometabolic, Diabetes, Hospital, Specialty and Primary Care.

 

Mr. Commissaris started his career in sales in the United Kingdom at Eli Lilly & Co and quickly took on roles of increasing responsibility in a number of commercial leadership positions. He spent the next 25 years building global brands, building teams, and launching products that made a difference in patients’ lives. He worked for Eli Lilly & Co and Astrazeneca in a variety of general management positions in Latin America, Southern Europe and Africa. Prior to joining Recordati Rare Diseases, Mr. Commissaris was the Vice President of the International Business at EUSA Pharma leading businesses in Japan, China, Asia Pacific (including Australia), Middle East, Turkey, Russia, Canada and Latin America.

 

Mr. Commissaris graduated from the Reading University, United Kingdom with a Bachelor of Science degree in Agricultural Botany. He holds an M.B.A. from Warwick Business School, United Kingdom.

Alessandro Albuquerque

CMO and Vice President Medical Affairs and Clinical Development

Alessandro Albuquerque is the Chief Medical Officer and Vice-President of Medical Affairs & Clinical Development at Recordati Rare Diseases, where he is responsible for medical affairs, clinical development, and clinical operations strategy and execution. Alessandro is also responsible for RRD North American Pharmacovigilance, Medical Information, Medical Operations, and HEOR. He has a master’s degree in Genetic Engineering and Biotechnology, a PhD in Medical Sciences, and a postgraduate in Drug Development and Regulation.

 

Prior to joining Recordati, Mr. Albuquerque was the Vice President for US Cardiovascular, Renal, and Metabolism at AstraZeneca, US Vice – President for Cardiovascular and Established Products at Sanofi, and Global Medical Lead for Cardiovascular and Metabolism at Amgen. His experience has allowed him to be part of many successful product launches for highly prevalent and rare diseases.

Max Johnson

General Manager, Canada

Max Johnson is Managing Director of Recordati Rare Diseases Canada, where he is responsible for continuing to grow and develop Recordati’s Canadian rare disease business. Max has over 20 years of Canadian, US and global commercial experience with a focus in rare diseases for the last ten years. Prior to joining the company, Max held positions of increasing responsibility at Wyeth-Ayerst, Allergan, Sanofi-Synthelabo, GlaxoSmithKline and ApoPharma.

 

Mr. Johnson received his B.Sc. (Biology) from Simon Fraser University and his MMSc (Management of Technology & Innovation) from Ryerson University.

Becky Zenz

Vice President, Human Resources

Becky Zenz is the Vice President of Human Resources at Recordati Rare Diseases. She brings over 25 years of human resources experience to the organization and is responsible for Recordati Rare Diseases’ human resources strategy; creating and leading programs for cultural progression, talent acquisition, employee engagement & development and total rewards. Prior to joining Recordati Rare Diseases, she worked for Temptime Corporation, a medical device manufacturing company in the role of Vice President, Human Resources. Becky has also held HR roles for companies in various industries and stages of business life cycle.


Becky earned her B.S. degree with honors in Hospitality Management from the University of New Haven, West Haven Connecticut.

Peter H. Strauss

Vice President Endocrinology Commercial Operations and Market Access

Pete Strauss was named Vice President of the Endocrinology Franchise in 2022. In addition to leading the commercial activities for Endocrinology, he is also responsible for Market Access and Patient Services across all business units. With over 27 years of experience in the pharmaceutical industry, Mr. Strauss has held multiple leadership positions focused on the commercialization of products across various therapeutic areas, including Rare Diseases, Hematology/Oncology, Hospital, Specialty and Primary Care.


He began his career at Pharmacia & Upjohn, advancing through roles of increasing responsibility. Mr. Strauss spent much of his career at major multinational corporations such as Pfizer, Schering-Plough, and Merck & Co., acquiring extensive commercial expertise, particularly in Sales, Marketing, Training, Operations, and Market Access. Mr. Strauss joined Recordati in 2020 and previously served as Vice President of the Metabolic Franchise.


Mr. Strauss holds a Bachelor of Science degree in Biology from the University of North Carolina-Charlotte and has pursued additional coursework at Duke University’s Fuqua School of Business.

Nick DeLong

Vice President of North American Business Development & Portfolio Management

Nick DeLong is the Vice President of North American Business Development and Portfolio Management at Recordati Rare Diseases. He has been helping companies identify and execute strategic and financial transactions for over 15 years. In his role at Recordati, his focus is on working with the global team to identify and execute deals that build and grow Recordati’s rare disease portfolio, as well as actively evaluating and managing opportunities to advance the company’s existing portfolio and pipeline.

 

Prior to joining Recordati, Nick was the head of business development at iBio, a small public oncology-focused drug discovery biotech, where he helped the company build its pipeline by leading multiple in-license and acquisition deals. He also served as head of business development for Tris Pharma, and spent 7 years at Locust Walk, a boutique investment bank which leads sell- and buy-side transactions for its clients.

 

Nick earned a Ph.D. in Neuroscience at the University of Pennsylvania, as well as a B.A. in biochemistry from Rutgers University.

Carter Clanton

Vice President, Metabolic Diseases Commercial Operations

Carter Clanton is the Vice President of Commercial Operations where he is responsible for leading Recordati’s Metabolic Franchise. During his career which spans 30+ years, Mr. Clanton has held numerous leadership positions focused on commercializing products across a variety of therapeutic categories including Oncology/Hematology, Rare Diseases, Hospital, Specialty and Primary Care.


Mr. Clanton started his career in sales at Marion Merrell Dow and quickly took on roles of increasing responsibility. He spent the next 25 years building global brands, building teams, and launching products that made a difference in patients’ lives. He worked for Immunex, MGI Pharma, Eisai, Prometheus Labs, Baxalta, and Shire; gaining broad commercial experience, most notably in leadership positions in Sales, Marketing (U.S. and Global), Sales Training, Operations, and Market Access. Prior to joining Recordati, Mr. Clanton was the Head of the US Commercial Team at EUSA Pharma.


Mr. Clanton graduated from the Wake Forest University with a Bachelor of Science degree in Biology.

Weicheng Wu

Vice President, Regulatory Affairs and Quality Assurance (GCP/GPV)

Weicheng Wu is Vice President, Regulatory Affairs and Quality Assurance (GCP/GPV) at Recordati Rare Diseases, where he is responsible for development and implementation of regulatory and quality strategies. He brings over 20 years of regulatory affairs and quality assurance experience, supporting development and commercialization of biologics, drugs, and medical devices.

 

Prior to joining Recordati Rare Diseases, Mr. Wu held positions of increasing responsibility in regulatory affairs and quality assurance at companies including ASC Therapeutics, Fosun Pharma USA, eVenus Pharmaceutical Laboratories, Qualitest Pharmaceuticals, Watson Pharmaceuticals, and Allergan.

 

Mr. Wu earned his B.S. in Biological Sciences & Biotechnology and M.S. in Biochemistry from Tsinghua University, and his M.S. in Regulatory Science and Ph.D. in Biochemistry & Molecular Biology from the University of Southern California.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site
Recordati for the planet
A clean environment is essential for people’s well-being: the health of the planet and the health of people is tightly interconnected. Environmental elements, such as air, water, land and climate, all have an impact on the well-being of humans. Placing a focus on people’s health and being sustainable therefore also means prioritising environmental protection and a responsibility towards future generations. This is why the Group ensures that it conducts business in a socially responsible manner and in accordance with sustainable practices, national and international laws, and the expectations of stakeholders.
Recordati for the community
We believe that contributing to the well-being of the community and dedicating part of our resources to acts of solidarity is not merely the fulfilment of company obligations or professional duty, but rather a moral imperative, an essential part of a healthy business capable of growth but at the same time able to support and develop the community in which it operates and make its employees proud.
Value and diversity of our people
At Recordati, we believe in equal opportunities and we guarantee that everyone can achieve their potential. We see diversity as a value and will not tolerate any discrimination based on ethnicity, nationality, gender, sexual orientation, disability, age, political or religious belief, or any other personal characteristics. At Recordati, we work hard to create a safe and inclusive work environment, where we all have our rights to physical and psychological integrity respected on a daily basis, as well as our right to freedom of opinion and association. We recognise that we each have a role to play in the success of our business and we implement staff development policies through which everyone’s contribution and achievements can be appropriately rewarded.
Multiple opportunities
Recordati is uniquely structured to bring treatment options across specialty and primary care, consumer healthcare, and rare diseases. We have fully integrated operations across research and development, chemical and finished product manufacturing through to commercialisation and licensing.
Luigi Longinotti
Managing Director and General Manager EMEA

Luigi Longinotti is Managing Director and General Manager for EMEA at Recordati Rare Diseases, leading the European and Middle Eastern Commercial Operations. He is responsible for Marketing, Medical, Market Access, Regulatory, Manufacturing and Logistics, as well as the enabling functions to support the business, including Compliance and Quality.

 

He joined Recordati in July 2014 as Corporate Portfolio Management Director for Orphan Drugs. In such a role he has been responsible for driving the growth of the rare disease portfolio at Recordati, with his duties ranging from business development to strategic marketing and pipeline project management.

 

Before he joined Recordati, he held senior business and corporate development roles at Chiesi Farmaceutici and Menarini Group where he executed several key asset deals and transactions.

Luigi gained a degree in Economics from the University of Florence and a Master’s degree in Business Innovation from Sant’Anna School of Advanced Studies in Pisa.

Bruno Parenti
Head of LAC Region, Head of Global Endocrinology Franchise

Bruno Parenti is Head of LAC Region at Recordati Rare Diseases, leading the business in Latin America, Asia Pacific and Russia. He has been in this position since 2011, where he spearheaded the expansion of operations around the globe. He recently assumed the additional role of Head of Global Endocrinology Franchise, establishing the new HQ in Basel and building a dedicated organization.

 

Prior to these positions, Bruno spent two years at Recordati Ireland overseeing international sales in the Asia-Pacific region. He served at Chiesi Farmaceutici for two years as Area Manager for the Far East. Earlier in his career, he held commercial roles at Kedrion Biopharmaceuticals where he was responsible for international markets with a focus on Latin America and the Middle East.

Scott Pescatore
Executive Vice President

Scott Pescatore is Vice President and Head of Global Operations at Recordati Rare Diseases.

He holds a Doctor of Pharmacy degree and completed his post-doctoral fellowship in Pharmacology and Drug Development. Dr Pescatore has spent over 20 years working internationally in the pharmaceutical industry, specializing in oncology, haematology and rare diseases.

 

He joined Novartis Oncology US in 2001 where he served in various medical, sales and marketing roles of increasing responsibility. In 2008, he moved to Novartis Oncology UK as Business Franchise Head for solid tumours where he also managed the New Products portfolio. In 2010 he moved to Milan to manage the Region Europe Haematology Franchise where he led the joint venture between Novartis Oncology and Incyte to launch a novel treatment for myeloproliferative disorders. In 2014 he was appointed the Oncology General Manager in Ireland and after three years returned to Milan as General Manager of the Region Europe Rare Disease Business Unit, overseeing operations in 37 markets and focusing on the endocrinology portfolio.

 

Prior to joining Recordati Rare Diseases in 2020, he was Vice President Oncology Business Unit for AstraZeneca Italy where he was responsible for the portfolio of oncology/haematology products including two joint ventures with MSD and Daiichi Sankyo.

You are about to leave this site and visit the recordati global website?

To continue please click the link below.

Visit Global Site